Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (366K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by McPike, M. P.
Right arrow Articles by Dabrowiak, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McPike, M. P.
Right arrow Articles by Dabrowiak, J. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2002, Vol. 30, No. 13 2825-2831
© 2002 Oxford University Press

Footprinting, circular dichroism and UV melting studies on neomycin B binding to the packaging region of human immunodeficiency virus type-1 RNA

Mark P. McPike, Julie M. Sullivan, Jerry Goodisman and James C. Dabrowiak*

Department of Chemistry, Center for Science and Technology, Room 1-014, Syracuse University, Syracuse, NY 13244-4100, USA

We have studied the binding of neomycin to a 171mer RNA ({psi}-RNA) from the packaging region of the LAI strain of human immunodeficiency virus type-1, HIV-1 (LAI). The RNase I footprinting studies reveal that the primary binding site for the drug is in stem–loop 1, which contains the dimer initiation site of HIV-1. Loading this site with neomycin causes a structural change in the RNA, allowing nucleotides in the neighboring stem–loop 2 to participate in the drug site. Drug binding to secondary sites induces structural changes in other stem–loops of the RNA. Footprinting plots, showing cutting at a site as a function of drug concentration, were analyzed using a two-state model to obtain relative site-specific binding constants. Circular dichroism measurements show that neomycin binding to {psi}-RNA changes the intensity of the strong negative CD band at 208 nm, confirming that neomycin induces structural changes. Melting studies of the RNA showed melting transitions in the absence of drug at 28.2, 37.2, 47.4, 55.5 and 60.8°C. Only the first two were affected by drug binding, the reason for this being explained by our analysis.

* To whom correspondence should be addressed. Tel: +1 315 443 4601; Fax: +1 315 443 4070; Email: jcdabrow{at}syr.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
K. B. Turner, N. A. Hagan, and D. Fabris
Inhibitory effects of archetypical nucleic acid ligands on the interactions of HIV-1 nucleocapsid protein with elements of {Psi}-RNA
Nucleic Acids Res., March 6, 2006; 34(5): 1305 - 1316.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
E. Ennifar, J.-C. Paillart, A. Bodlenner, P. Walter, J.-M. Weibel, A.-M. Aubertin, P. Pale, P. Dumas, and R. Marquet
Targeting the dimerization initiation site of HIV-1 RNA with aminoglycosides: from crystal to cell.
Nucleic Acids Res., January 1, 2006; 34(8): 2328 - 2339.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Ennifar, J.-C. Paillart, R. Marquet, B. Ehresmann, C. Ehresmann, P. Dumas, and P. Walter
HIV-1 RNA Dimerization Initiation Site Is Structurally Similar to the Ribosomal A Site and Binds Aminoglycoside Antibiotics
J. Biol. Chem., January 17, 2003; 278(4): 2723 - 2730.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.